|
|
|
|
|
|
|
|
| Donna Mendrick, PhD, VP, Toxicogenomics, Gene Logic |
|
| Dr. Mendrick has twenty-four years of experience in the fields of pharmacogenomics, toxicology, pharmacology, immunology and pathology with in vivo and in vitro systems. She joined Gene Logic in 1998 to spearhead its toxicogenomics effort and formed a pharmaceutical consortium to help guide the development of the program. Dr. Mendrick continues to serve as a member of the steering committee for the FDA co-sponsored Workshops on the use of genomic data in the regulatory environment and is on the Predictive Toxicology program committee at the New York Academy of Sciences. She has spoken on the use of pharmacogenomics to wide-ranging audiences including the Woodrow Wilson International Center for Scholars (November, 2002), the Committee on Emerging Issues and Data on Environmental Contaminants at The National Academy of Sciences (February, 2003 and August, 2004), the PhRMA/FDA Genomics (Microarray) Biostatistics Workshop held in April of 2004, and the EPA Science Forum (May 2003). Dr. Mendrick was on the Editorial Board of the Journal of Histochemistry and Cytochemistry for 8 years, a member of the NIH SBIR Immunology Study Section for 8 years, and a member of the Board of Directors of the National Kidney Foundation of Massachusetts for 4 years. Prior to joining Gene Logic in 1998, Dr. Mendrick was a Group Leader in Pharmacology at Human Genome Sciences Inc. where she directed several Project Teams and planned and supervised pharmacology and toxicology experiments. Prior to joining Human Genome Sciences she was an Assistant Professor in the Department of Pathology at Harvard Medical School where her research focused on renal immunopathology and endothelial biology.
|
|
|
|
|
|
|
|
|
|
|
